Exelixis Inc. (EXEL)
NASDAQ: EXEL · Biological Products, (No Diagnostic Substances) · Alameda, CA
Our rating: Neutral
Call changed from Positive to Neutral at $69.39, moderate conviction, October 30, 2026.
Breaks if: The call turns Positive if revenue growth re-accelerates to 12% or above for two consecutive reported quarters, signaling franchise expansion that genuinely earns the premium multiple. It turns Cautious if net margin falls below 25% for two straight quarters — indicating the cost or competitive picture has shifted — or if annual revenue growth drops below 3%, compressing earnings against an unchanged elevated multiple. Neither condition is true at today's reported figures.
Key figures
| Market value | $15.8B |
|---|---|
| Revenue, last 12 months | $2.5B |
| Net income, last 12 months | $885M |
| Free cash flow, last 12 months | $1.2B |
| Price to earnings | 17.8× |
| Free cash flow yield | 7.4% |
| Dividend yield | 0.0% |
| Operating margin | 40.2% |
| Return on equity | 44.3% |
| Beta to the S&P 500 | 0.54 |
| Volatility, annualized | 38.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| October 2, 2026 | $659M | 10.2% | $0.85 | $277M |
| July 3, 2026 | $629M | 10.6% | $0.82 | $301M |
| April 3, 2026 | $611M | 10.0% | $0.79 | $250M |
| January 2, 2026 | $599M | 5.6% | $0.88 | $332M |
| October 3, 2025 | $598M | 10.8% | $0.69 | $289M |
| July 4, 2025 | $568M | −10.8% | $0.65 | $46M |
| April 4, 2025 | $555M | 30.6% | $0.55 | $208M |
| January 3, 2025 | $567M | 18.2% | $0.48 | $236M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.65B: Claude 72%, Gemini 95%, Mistral 82%
- Diluted earnings per share are at least $0.88: Claude 45%, Gemini 70%, Mistral 68%
- Free cash flow for the quarter is at least $0.33B: Claude 38%, Gemini 25%, Mistral 42%
10 ledger entries and 26 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.